A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil

Clinical Colorectal Cancer

Volumn 3, Issue 3, 2003, Pages 174-179

  Méndez, Miguel ^a   Salut, Antonieta ^b   García Girón, Carlos ^c   Navalon, Marta ^d   Diz, Pilar ^e   García López, Maria José ^f   España, Pilar ^g   de la Torre, Ascensión ^h   Martínez del Prado, Purificación ⁱ   Duarte, Isabel ^j   Pujol, Eduardo ^k   Arizcun, Alberto ^l   Cruz, Juan Jesús ^m  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^d Hospital General de Zamora   (Spain)

^e Hospital Virgen Blanca   (Spain)

^f Hospital Alarcos   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

ⁱ HOSPITAL DE BASURTO   (Spain)

^j HOSPITAL VIRGEN DEL PUERTO   (Spain)

^k HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^l HOSPITAL RÍO CARRIÓN   (Spain)

^m HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

5 FU resistance; Cholinergic syndrome; Diarrhea; Palliative chemotherapy

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEARTBURN; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 9144263660     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2003.n.023     Document Type: Article

References (26)

1. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer 1999; 35:371-379.
2. Royce ME, Medgyesy D, Zukowski TH, et al. Colorectal cancer. chemotherapy treatment overview. Oncology (Huntingt) 2000; 14:40-46.
3. Sobrero A, Kerr D, Glimelius B, et al. New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer 2000; 36:559-566.
4. Rougier P, Mitry E. Epidemiology, treatment and chemoprevention in colorectal cancer. Ann Oncol 2003; 14(suppl 2):113-115.
5. Rougier P, Mitry E. Colorectal cancer chemotherapy: irinotecan. Semin Oncol 2000; 27:138-143.
6. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
7. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-1412.
8. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:251-260.
9. Freyer G, Rougier P, Bugat R, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT- 11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer 2000; 83:431-437.
10. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
11. Guidelines for the reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
12. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-151.
13. Zaniboni A, Labianca R, Martignoni G, et al. Sequential methotrexate and 5-fluorouracil as second-line chemotherapy for advanced colorectal cancer patients pretreated with 5-fluorouracil and leucovorin: a GISCAD study. J Chemother 1996; 8:82-84.
14. Aravantinos G, Skarlos DV, Kosmidis P, et al. Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy. Crit Rev Oncol Hematol 1999; 32:209-219.
15. Iveson TJ, Hickish T, Schmitt C, et al. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer 1999; 35:1796-1804.
16. Van Cutsem E, Blijham GH. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. Semin Oncol 1999; 26:13-20.
17. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999; 35:54-59.
18. Ychou M, Douillard JY, Rougier P, et al. Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open- label multicenter phase II study. Am J Clin Oncol 2000; 23:143-148.
19. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 11:909-913.
20. Isacoff WH, Borud K. Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. World J Surg 1997; 21:748-762.
21. Van Cutsem E, Douillard JY, Kohne CH. Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 2001; 345:1351-1352.
22. Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19:1501-1518.
23. Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996; 52:606-623.
24. Stucky-Marshall L. New agents in gastrointestinal malignancies: Part 1: Irinotecan in clinical practice. Cancer Nurs 1999; 22:212-219.
25. Nikolic-Tomasevic Z, Jelic S, Popov I, et al. Colorectal cancer: dilemmas regarding patient selection and toxicity prediction. J Chemother 2000; 12:244-251.
26. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807-814.